{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:30:09Z","timestamp":1782937809279,"version":"3.54.5"},"reference-count":60,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0317-y","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T13:21:32Z","timestamp":1516108892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop"],"prefix":"10.1136","volume":"6","author":[{"given":"Ariel E.","family":"Marciscano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Kunos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arta M.","family":"Monjazeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Shiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"issue":"7","key":"317_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409\u201325.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"317_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862\u201370.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"317_CR3","first-page":"6028","volume":"59","author":"PK Chakravarty","year":"1999","unstructured":"Chakravarty PK, Alfieri A, Thomas EK, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res. 1999;59(24):6028\u201332.","journal-title":"Cancer Res"},{"issue":"2 Pt 1","key":"317_CR4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(2 Pt 1):728\u201334.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"317_CR5","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"317_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","volume":"1","author":"EB Golden","year":"2013","unstructured":"Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365\u201372.","journal-title":"Cancer Immunol Res"},{"issue":"137","key":"317_CR7","doi-asserted-by":"publisher","first-page":"137ra74","DOI":"10.1126\/scitranslmed.3003649","volume":"4","author":"SK Seung","year":"2012","unstructured":"Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med. 2012;4(137):137ra74.","journal-title":"Sci Transl Med"},{"issue":"305","key":"317_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234\u201341.","journal-title":"Br J Radiol"},{"issue":"4","key":"317_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ijrobp.2012.06.020","volume":"84","author":"SC Formenti","year":"2012","unstructured":"Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84(4):879\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"317_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","volume":"14","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365\u201379.","journal-title":"Nat Rev Clin Oncol"},{"key":"317_CR11","doi-asserted-by":"publisher","unstructured":"Vanpouille-Box C, Formenti SC, Demaria S. Towards precision radiotherapy for use with immune checkpoint blockers. Clin Cancer Res. 2017. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0037","DOI":"10.1158\/1078-0432.CCR-16-0037"},{"issue":"6","key":"317_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","volume":"41","author":"K Reynders","year":"2015","unstructured":"Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41(6):503\u201310.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"317_CR13","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379\u201388.","journal-title":"Clin Cancer Res"},{"key":"317_CR14","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"issue":"5","key":"317_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843\u201352.","journal-title":"Immunity"},{"issue":"4","key":"317_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000096288","volume":"70","author":"PK Chakravarty","year":"2006","unstructured":"Chakravarty PK, Guha C, Alfieri A, et al. Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: its implication in designing a vaccination strategy. Oncology. 2006;70(4):245\u201354.","journal-title":"Oncology"},{"issue":"6","key":"317_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.18632\/oncoscience.48","volume":"1","author":"S Saha","year":"2014","unstructured":"Saha S, Bhanja P, Partanen A, et al. Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG. Oncoscience. 2014;1(6):434\u201345.","journal-title":"Oncoscience"},{"key":"317_CR18","doi-asserted-by":"publisher","unstructured":"Bandyopadhyay S, Quinn TJ, Scandiuzzi L, et al. Low-intensity focused ultrasound induces reversal of tumor-induced T cell tolerance and prevents immune escape. J Immunol. 2016;196(4):1964\u201376. https:\/\/doi.org\/10.4049\/jimmunol.1500541 .","DOI":"10.4049\/jimmunol.1500541"},{"issue":"1","key":"317_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40880-017-0216-5","volume":"36","author":"Y Takahashi","year":"2017","unstructured":"Takahashi Y, Matsutani N, Nakayama T, Dejima H, Uehara H, Kawamura M. Immunological effect of local ablation combined with immunotherapy on solid malignancies. Chin J Cancer. 2017;36(1):5.","journal-title":"Chin J Cancer"},{"issue":"2","key":"317_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/0008-5472.CAN-11-1782","volume":"72","author":"R Waitz","year":"2012","unstructured":"Waitz R, Solomon SB, Petre EN, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72(2):430\u20139.","journal-title":"Cancer Res"},{"issue":"5","key":"317_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-15-1352","volume":"22","author":"L Shi","year":"2016","unstructured":"Shi L, Chen L, Wu C, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res. 2016;22(5):1173\u201384.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"317_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-016-1891-9","volume":"66","author":"RJ van den Bijgaart","year":"2017","unstructured":"van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, Futterer JJ, den Brok MH, Adema GJ. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017;66(2):247\u201358.","journal-title":"Cancer Immunol Immunother"},{"key":"317_CR23","doi-asserted-by":"publisher","unstructured":"Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(14)70189-5 .","DOI":"10.1016\/S1470-2045(14)70189-5"},{"key":"317_CR24","doi-asserted-by":"publisher","unstructured":"Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology. 2013;81(6):1297\u2013302. https:\/\/doi.org\/10.1016\/j.urology.2013.01.061 .","DOI":"10.1016\/j.urology.2013.01.061"},{"key":"317_CR25","doi-asserted-by":"publisher","unstructured":"Radwan N, Phillips R, Ross A, et al. A phase II randomized trial of observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer. 2017;17(1):6. https:\/\/doi.org\/10.1186\/s12885-017-3455-6.","DOI":"10.1186\/s12885-017-3455-6."},{"issue":"6264","key":"317_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M Vetizou","year":"2015","unstructured":"Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079\u201384.","journal-title":"Science"},{"issue":"1","key":"317_CR27","doi-asserted-by":"publisher","first-page":"e1132137","DOI":"10.1080\/2162402X.2015.1132137","volume":"6","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Vetizou M, Gomperts Boneca I, Lepage P, Chamaillard M, Zitvogel L. Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. Oncoimmunology. 2016;6(1):e1132137.","journal-title":"Oncoimmunology"},{"issue":"6264","key":"317_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084\u20139.","journal-title":"Science"},{"key":"317_CR29","doi-asserted-by":"publisher","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","DOI":"10.1126\/science.aan4236"},{"key":"317_CR30","doi-asserted-by":"publisher","unstructured":"Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","DOI":"10.1126\/science.aan3706"},{"key":"317_CR31","doi-asserted-by":"publisher","unstructured":"Gulley JL, Berzofsky JA, Butler MO, et al. Immunotherapy biomarkers 2016: overcoming the barriers. J Immunother Cancer. 2017;5(1):6. https:\/\/doi.org\/10.1186\/s40425-017-0225-6 .","DOI":"10.1186\/s40425-017-0225-6"},{"issue":"23","key":"317_CR32","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399.","journal-title":"N Engl J Med"},{"issue":"6230","key":"317_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"4","key":"317_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.semradonc.2015.05.001","volume":"25","author":"AA Chaudhuri","year":"2015","unstructured":"Chaudhuri AA, Binkley MS, Osmundson EC, Alizadeh AA, Diehn M. Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA. Semin Radiat Oncol. 2015;25(4):305\u201312.","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"317_CR35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548\u201354.","journal-title":"Nat Med"},{"issue":"1","key":"317_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2159-8290.CD-16-0127","volume":"7","author":"Y Jeong","year":"2017","unstructured":"Jeong Y, Hoang NT, Lovejoy A, et al. Role of KEAP1\/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov. 2017;7(1):86\u2013101.","journal-title":"Cancer Discov"},{"key":"317_CR37","doi-asserted-by":"publisher","unstructured":"Heskamp S, Raave R, Boerman OC, Rijpkema M, Goncalves V, Denat F. (89)zr-immuno-positron emission tomography in oncology: State-of-the-art (89)zr radiochemistry. Bioconjug Chem. 2017;28(9):2211\u201323. https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00325","DOI":"10.1021\/acs.bioconjchem.7b00325"},{"issue":"31","key":"317_CR38","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2012.42.4887","volume":"30","author":"SM Knowles","year":"2012","unstructured":"Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30(31):3884\u201392.","journal-title":"J Clin Oncol"},{"key":"317_CR39","doi-asserted-by":"publisher","unstructured":"Natarajan A, Mayer AT, Reeves RE, Nagamine CM, Gambhir SS. Development of novel ImmunoPET tracers to image human PD-1 checkpoint expression on tumor-infiltrating lymphocytes in a humanized mouse model. Mol Imaging Biol. 2017;19(6):903\u2013914. https:\/\/doi.org\/10.1007\/s11307-017-1060-3","DOI":"10.1007\/s11307-017-1060-3"},{"key":"317_CR40","doi-asserted-by":"publisher","first-page":"153601211771845","DOI":"10.1177\/1536012117718459","volume":"16","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Lesniak WG, Nimmagadda S. Noninvasive imaging of immune checkpoint ligand PD-L1 in tumors and metastases for guiding immunotherapy. Mol Imaging. 2017;16:1536012117718459.","journal-title":"Mol Imaging"},{"key":"317_CR41","doi-asserted-by":"publisher","unstructured":"Young KH, Baird JR, Savage T, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS One. 2016;11(6):e0157164. https:\/\/doi.org\/10.1371\/journal.pone.0157164 .","DOI":"10.1371\/journal.pone.0157164"},{"key":"317_CR42","doi-asserted-by":"publisher","unstructured":"Dodd RD, Ano L, Blum JM, Li Z, Van Mater D, Kirsch DG. Methods to generate genetically engineered mouse models of soft tissue sarcoma. Methods Mol Biol. 2015;1267:283\u201395. https:\/\/doi.org\/10.1007\/978-1-4939-2297-0_13 .","DOI":"10.1007\/978-1-4939-2297-0_13"},{"key":"317_CR43","doi-asserted-by":"publisher","unstructured":"Ahn E, Youngblood B, Lee J, Lee J, Sarkar S, Ahmed R. Demethylation of the PD-1 promoter is imprinted during the effector phase of CD8 T cell exhaustion. J Virol. 2016;90(19):8934\u201346. https:\/\/doi.org\/10.1128\/JVI.00798-16 .","DOI":"10.1128\/JVI.00798-16"},{"key":"317_CR44","doi-asserted-by":"publisher","unstructured":"Schietinger A, Philip M, Krisnawan VE, et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity. 2016;45(2):389\u2013401. https:\/\/doi.org\/10.1016\/j.immuni.2016.07.011.","DOI":"10.1016\/j.immuni.2016.07.011."},{"key":"317_CR45","doi-asserted-by":"publisher","unstructured":"Ghoneim HE, Fan Y, Moustaki A, et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 2017;170(1):157.e19. https:\/\/doi.org\/10.1016\/j.cell.2017.06.007 .","DOI":"10.1016\/j.cell.2017.06.007"},{"key":"317_CR46","doi-asserted-by":"publisher","unstructured":"Mathios D, Kim JE, Mangraviti A, et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med. 2016;8(370):370ra180. https:\/\/doi.org\/10.1126\/scitranslmed.aag2942 .","DOI":"10.1126\/scitranslmed.aag2942"},{"key":"317_CR47","doi-asserted-by":"publisher","unstructured":"Kim JE, Patel MA, Mangraviti A, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2017;23(1):124\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1535 .","DOI":"10.1158\/1078-0432.CCR-15-1535"},{"key":"317_CR48","doi-asserted-by":"publisher","unstructured":"Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.12.025 .","DOI":"10.1016\/j.ijrobp.2012.12.025"},{"issue":"7637","key":"317_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"10","key":"317_CR50","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014\u201322.","journal-title":"Nat Immunol"},{"key":"317_CR51","doi-asserted-by":"publisher","unstructured":"Aguilera TA, Rafat M, Castellini L, et al. Reprogramming the immunological microenvironment through radiation and targeting axl. Nat Commun. 2016;7:13898. https:\/\/doi.org\/10.1038\/ncomms13898.","DOI":"10.1038\/ncomms13898."},{"key":"317_CR52","doi-asserted-by":"publisher","unstructured":"Crittenden MR, Baird J, Friedman D, et al. Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. Oncotarget. 2016;7(48):78653\u201366. https:\/\/doi.org\/10.18632\/oncotarget.11823.","DOI":"10.18632\/oncotarget.11823."},{"issue":"6","key":"317_CR53","doi-asserted-by":"publisher","first-page":"1554.e12","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1554.e12.","journal-title":"Cell"},{"issue":"7547","key":"317_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.","journal-title":"Nature"},{"key":"317_CR55","doi-asserted-by":"publisher","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1223 .","DOI":"10.1158\/2159-8290.CD-16-1223"},{"key":"317_CR56","doi-asserted-by":"publisher","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1604958.","DOI":"10.1056\/NEJMoa1604958."},{"key":"317_CR57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fimmu.2017.00229","volume":"8","author":"E Wennerberg","year":"2017","unstructured":"Wennerberg E, Lhuillier C, Vanpouille-Box C, et al. Barriers to radiation-induced in situ tumor vaccination. Front Immunol. 2017;8:229.","journal-title":"Front Immunol"},{"issue":"2","key":"317_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1667\/RR13374.1","volume":"182","author":"MM Wattenberg","year":"2014","unstructured":"Wattenberg MM, Fahim A, Ahmed MM, Hodge JW. Unlocking the combination: Potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res. 2014;182(2):126\u201338.","journal-title":"Radiat Res"},{"key":"317_CR59","doi-asserted-by":"publisher","unstructured":"Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548(7668):466\u201370. https:\/\/doi.org\/10.1038\/nature23470","DOI":"10.1038\/nature23470"},{"issue":"2","key":"317_CR60","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","volume":"18","author":"JG Scott","year":"2017","unstructured":"Scott JG, Berglund A, Schell MJ, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017;18(2):202\u201311.","journal-title":"Lancet Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0317-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T17:19:50Z","timestamp":1660324790000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0317-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["317"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0317-y","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,29]]},"assertion":[{"value":"21 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HMM served on an advisory board for AstraZeneca. MMK has received research funding from EpicentRx. AMM has clinical trial funding and\/or served on an advisory board for Transgene, Incyte, Genentech, Merck, EMD Serono, Dynavax, AstraZeneca. PTT served on the medical advisory board for Dendreon Pharmaceuticals, Inc. and is a consortium member for RefleXion Medical. The remaining authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"6"}}